Back |
home / stock / ptn / ptn message board
Subject | By | Source | When |
---|---|---|---|
I will take 50,60 or 70 company will | zeusgodmd | investorshub | 12/23/2022 10:00:15 PM |
Does not look like a stock going off | zeusgodmd | investorshub | 12/22/2022 8:10:02 PM |
Doubled my bet today | zeusgodmd | investorshub | 12/22/2022 4:42:47 PM |
No company will be bought before eye drops | zeusgodmd | investorshub | 12/22/2022 4:42:20 PM |
I don't know but $PTN stock price is | mike1986 | investorshub | 12/08/2022 5:13:05 PM |
Do analyst stated price targets have any real | BesaoT35 | investorshub | 11/22/2022 7:14:04 PM |
Given 70 price up grade and going down | zeusgodmd | investorshub | 11/16/2022 10:53:37 PM |
Every time this company says boo there is | mike1986 | investorshub | 11/14/2022 7:28:36 PM |
Correction: The disease addressed in the presentation | BesaoT35 | investorshub | 10/28/2022 4:41:43 PM |
$PTN is up 20% in the past few | BesaoT35 | investorshub | 10/26/2022 6:25:04 PM |
I hadnt considered management getting paid to stifle | BesaoT35 | investorshub | 09/27/2022 2:39:54 PM |
You are exactly right. Men should not be | Monroe1 | investorshub | 09/22/2022 9:12:51 PM |
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Sympt...
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 PR Newswire CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 20...
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar ye...